Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 60 or younger (some disease-specific exceptions may apply — confirm with trial site)
• People with a reasonable level of physical functioning, as measured by standard performance scales used by doctors
• People (or their parent, guardian, or legal representative) who are willing and able to give written consent to participate
• People whose kidneys are working at an acceptable level, based on blood or urine tests
• People whose liver is working at an acceptable level, based on blood tests
• People whose lungs are working at an acceptable level, based on breathing tests (for children unable to do breathing tests, a blood oxygen level above 95% on room air may be acceptable)
• People whose heart is working at an acceptable level, with no uncontrolled irregular heartbeat or severe heart failure, and a heart pumping function above a certain level (for children unable to cooperate with heart tests, the doctor must document this)
• People living with HIV, provided their viral load is undetectable and a HIV management plan has been set up with an Infectious Disease specialist before the transplant
• People who agree to use adequate birth control during treatment, if they are able to have children or have a partner who is able to have children
• People for whom a suitable donor or graft is available according to the transplant program's current standards
• People with one of the following blood cancers or related conditions, at the stage or disease status listed below (confirm with trial site for full details):
• Acute Myeloid Leukemia (AML) in second or later remission, or in first remission if it is not considered low-risk, or if the person is over 60
• Acute Prolymphocytic Leukemia (APL) in first molecular remission after consolidation treatment
• Certain very high-risk younger patients (under 21) with AML who have a small number of blasts remaining after chemotherapy
• Acute Lymphoblastic Leukemia (ALL) or lymphoma in second or later remission, or in first remission if it is high-risk or if the person could not tolerate standard chemotherapy
• Certain very high-risk younger patients (under 21) with ALL who have achieved a complete remission
• Chronic Myelogenous Leukemia (CML) in first chronic phase, if standard targeted therapy has not worked or was not tolerated; or in later phases excluding certain advanced stages
• Plasma Cell Leukemia, after initial treatment, if at least a partial response has been achieved
• Myeloproliferative conditions or myelofibrosis classified as intermediate or high risk, with a low number of abnormal cells in the bone marrow
• Myelodysplastic Syndrome (MDS) that is classified as higher risk, or with severe blood count problems, transfusion dependence, or high-risk genetic features, with a low number of abnormal cells in the bone marrow
• Certain types of slow-growing lymphoma (including CLL, SLL, Marginal Zone, or Follicular Lymphoma) that have relapsed or progressed within 12 months of a previous response, or after at least two prior treatments if remission lasted longer than 12 months
• Certain other lymphoma types (including Lymphoplasmacytic, Mantle Cell, or Prolymphocytic Leukemia) after initial treatment with at least a partial response
• Diffuse Large Cell Lymphoma that has relapsed quickly or where autologous transplant has failed or is not suitable
• Lymphoblastic Lymphoma, Burkitt's Lymphoma, or other high-grade lymphoma at advanced stage in first remission or response, or progressed within one year if at an earlier stage
• Multiple Myeloma beyond a second partial response, with certain higher-risk features
• Juvenile Myelomonocytic Leukemia
• Certain mixed or rare leukemia types in first or later remission
• Leukemia with measurable remaining disease detected by specialised testing, where recent chemotherapy has not cleared it
• Natural Killer Cell Malignancies
• Acquired Bone Marrow Failure Syndromes (excluding Fanconi Anaemia or Dyskeratosis Congenita)
• Other leukemia subtypes identified as high risk, with approval from at least two members of the study committee

Who may not be able to join:

• People with large cell or high-grade lymphoma that has not responded to chemotherapy and has continued to progress after more than two attempts at further treatment
• People with CML in blast crisis (an advanced, rapidly progressing stage)
• People with large cell lymphoma, mantle cell lymphoma, or Hodgkin disease that is getting worse despite further treatment
• People with signs that their disease is actively progressing, based on scans or biopsy results (note: certain scan findings alone, without other evidence of progression, may not automatically exclude someone — confirm with trial site)
• People with active cancer affecting the central nervous system (brain or spinal cord)
• People aged 18 or younger who have had an intensive (myeloablative) transplant within the last 6 months
• People aged over 18 who have previously had any intensive transplant, either using their own cells or a donor's cells
• People with active, uncontrolled HIV infection, or who are known to be HIV positive with detectable virus (note: people with HIV who have an undetectable viral load may still be eligible — see inclusion criteria above)
• People with an active infection that is not under control
• People who are pregnant or breastfeeding, as the medications used in this trial are known to be harmful to a developing baby; a negative pregnancy test is required before starting treatment for anyone who could become pregnant

Important: Always verify eligibility with the trial site directly before applying.